Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Clin. transl. oncol. (Print)
; 24(6): 1209-1214, junio 2022. tab
Article
em En
| IBECS
| ID: ibc-203820
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
PurposeSome patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications.MethodsRAS mutant genes in solid biopsy (before first-line treatment FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment panitumumab + FOLFIRI), using Idylla system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies).ResultsTwenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla system vs. NGS test).ConclusionThirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
Palavras-chave
Texto completo:
1
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Neoplasias Colorretais
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Panitumumabe
Limite:
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2022
Tipo de documento:
Article